A pilot study of a novel poly (ADP-ribose) polymerase-1 (PARP) PET tracer ([18F]FluorThanatrace) in patients with ovarian carcinoma
Conclusion: Preliminary results of this phase I pilot study demonstrate FTT localizes to areas of known ovarian cancer with a wide dynamic range of uptake FTT measures correlated well with in vitro markers of PARP-1, while uptake of FDG did not. These data suggest that FTT holds promise as a non-invasive measure of PARP-1 expression and warrants further study as a predictive biomarker for response to DNA-damaging agents. Research Support: Supported by Marsha Rivkin Ovarian Cancer Foundation, Kaleidoscope of Hope, Department of Energy (DE-SE0012476), NIH training grant (T32-EB004311).
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Pantel, A., MaKvandi, M., Doot, R., Schwartz, L., Greenberg, R., Simpkins, F., Mankoff, D., Lin, L., Mach, R. Tags: New Clinical Concepts and First-in-Human Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | CT Scan | Epithelial Cancer | Fallopian Tube Cancer | Gastroschisis Repair | Grants | Hepatocellular Carcinoma | Liver | Liver Cancer | Nuclear Medicine | Ovarian Cancer | Ovaries | Peritoneal Cancer | PET Scan | Radiation Therapy | Study | Training | Universities & Medical Training | Urology & Nephrology | Women